Sectoral Capsule-Vaccines Market in India (2009-2018)
In 2012, about 2 million people died from diseases which could have been prevented by vaccination.The Disability Adjusted Life Year (DALY) in India, for the year 2012, was 39,496 years, where DALY isthe number of years lost due to poor health, disability and early deaths. For the year, India’smortality count stood at 1,800. The major segments of the Indian vaccine market are UniversalImmunization Program++ (UIP++), post-incident vaccines, emerging mandatory vaccines, regularoptional vaccines, one-time optional vaccines and pulse polio vaccines. With a Compound AnnualGrowth rate (CAGR) of 20 percent through 2013-2018, the projected revenue is expected to be USD1193.83 million by 2018.
In 2012, the share of bio-pharmaceuticals in the biotechnology market was 64 percent. High exportvalue of bio-pharmaceutical products and an increase of 5 percent in sales per annum in 2012 can beattributed to its dominant share among the biotechnology segments. Health consciousness acrossthe globe has had its impact on India as well, resulting in strong sales of vaccines. In addition,existing vaccines have lowered the rate of infectious diseases to some extent, leading to customerbuy-ins.
In 2011, there were 26 R&D institutions in India which were working towards bringing in newvaccines in the market. In 2014, the Indian government announced the introduction of vaccines tofight rotavirus, rubella, polio and Japanese encephalitis. This can save at least 100,000 infants fromthese diseases. However, it is necessary to address certain constraints. These are issues relating tothe distribution of products, maintenance of high quality, long time frame of clinical trials and poorvaccination system in Indian poultry. India’s under-penetrated vaccine market can achieve a highgrowth trajectory if efforts are made by the government and institutions to streamline vaccinedevelopment in the country.